

North America Cephalosporin Drugs Market (2019-2025)

<https://marketpublishers.com/r/NFFE64039D0EN.html>

Date: July 2019

Pages: 98

Price: US\$ 1,500.00 (Single User License)

ID: NFFE64039D0EN

Abstracts

The North America Cephalosporin Drugs Market would witness market growth of 4.69% CAGR during the forecast period (2019–2025). Market growth is driven by the implementation of combination drugs like various antibacterials or antibacterials coupled with an inhibitor. It is anticipated that the use of combination drugs will reduce the likelihood of developing antibiotic-resistant bacterial strains, which is supposed to boost the market growth.

Compared to the first and second generations, Cephalosporin Drugs of the third generation are more efficient against Gram-negative bacteria. They are also more effective against bacteria that can be resistant to prior Cephalosporin Drugs generations. Cefepime (Maxipime) is the only Cephalosporin Drugs of the fourth generation accessible in the U.S. Although it is efficient against a multitude of Gram-positive and Gram-negative organisms, it is generally reserved for more serious diseases. The fifth-generation Cephalosporin Drugs, ceftaroline (Teflaro) may be used to treat bacteria that are resistant to penicillin antibiotics, including resistant species *Staphylococcus aureus* (MRSA) and *Streptococcus*.

Based on Generation, the market is segmented into First-Generation Cephalosporin, Second-Generation Cephalosporin, Third-Generation Cephalosporin, Fourth-Generation Cephalosporin, and Fifth-Generation Cephalosporin. Based on Application, the market is segmented into Respiratory Tract Infection, Skin Infection, Ear Infection, Sexually Transmitted Infection and Others. Based on Route of Administration, the market is segmented into Injections and Oral Drugs. Based on Type, the market is segmented into Branded and Generic. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include ABBOTT Laboratories, Teva Pharmaceuticals Industries Ltd., Johnson and Johnson, GlaxoSmithKline PLC (GSK), Pfizer, Inc., Merck & Co., Inc., Bayer AG, Baxter International, Inc., Bristol-Myers Squibb Company and Novartis AG.

Scope of the Study

Market Segmentation:

By Generation

First-Generation Cephalosporin

Second-Generation Cephalosporin

Third-Generation Cephalosporin

Fourth-Generation Cephalosporin

Fifth-Generation Cephalosporin

By Application

Respiratory Tract Infection

Skin Infection

Ear Infection

Sexually Transmitted Infection

Others

By Route of Administration

Injections

Oral Drugs

By Type

Branded

Generic

By Country

US

Canada

Mexico

Rest of North America

Companies Profiled

ABBOTT Laboratories

Teva Pharmaceuticals Industries Ltd.

Johnson and Johnson

GlaxoSmithKline PLC (GSK)

Pfizer, Inc.

Merck & Co., Inc.

Bayer AG

Baxter International, Inc.

BRISTOL-MYERS SQUIBB COMPANY

Novartis AG

Unique Offerings from KBV Research

Exhaustive coverage

Highest number of market tables and figures

Subscription based model available

Guaranteed best price

Assured post sales research support with 10% customization free

Contents

CHAPTER 1. MARKET SCOPE & METHODOLOGY

- 1.1 Market Definition
- 1.2 Objectives
- 1.3 Market Scope
- 1.4 Segmentation
 - 1.4.1 North America Cephalosporin Drugs Market, by Generation
 - 1.4.2 North America Cephalosporin Drugs Market, by Application
 - 1.4.3 North America Cephalosporin Drugs Market, by Route of Administration
 - 1.4.4 North America Cephalosporin Drugs Market, by Type
 - 1.4.5 North America Cephalosporin Drugs Market, by Country
- 1.5 Methodology for the research

CHAPTER 2. MARKET OVERVIEW

- 2.1 Introduction
 - 2.1.1 Overview
- 2.2 Key Factors Impacting the Market
 - 2.2.1 Market Drivers
 - 2.2.2 Market Restraints

CHAPTER 3. NORTH AMERICA CEPHALOSPORIN DRUGS MARKET BY GENERATION

- 3.1 North America First-Generation Cephalosporin Drugs Market by Country
- 3.2 North America Second-Generation Cephalosporin Drugs Market by Country
- 3.3 North America Third-Generation Cephalosporin Drugs Market by Country
- 3.4 North America Fourth-Generation Cephalosporin Drugs Market by Country
- 3.5 North America Fifth-Generation Cephalosporin Drugs Market by Country

CHAPTER 4. NORTH AMERICA CEPHALOSPORIN DRUGS MARKET BY APPLICATION

- 4.1 North America Respiratory Tract Infection Market by Country
- 4.2 North America Skin Infection Market by Country
- 4.3 North America Ear Infection Market by Country
- 4.4 North America Sexually Transmitted Infection Market by Country

4.5 North America Others Market by Country

CHAPTER 5. NORTH AMERICA CEPHALOSPORIN DRUGS MARKET BY ROUTE OF ADMINISTRATION

5.1 North America Injections Market by Country

5.2 North America Oral Drugs Market by Country

CHAPTER 6. NORTH AMERICA CEPHALOSPORIN DRUGS MARKET BY TYPE

6.1 North America Branded Market by Country

6.2 North America Generic Market by Country

CHAPTER 7. NORTH AMERICA CEPHALOSPORIN DRUGS MARKET BY COUNTRY

7.1 USA Cephalosporin Drugs Market

7.1.1 USA Cephalosporin Drugs Market by Generation

7.1.2 USA Cephalosporin Drugs Market by Application

7.1.3 USA Cephalosporin Drugs Market by Route of Administration

7.1.4 USA Cephalosporin Drugs Market by Type

7.2 Canada Cephalosporin Drugs Market

7.2.1 Canada Cephalosporin Drugs Market by Generation

7.2.2 Canada Cephalosporin Drugs Market by Application

7.2.3 Canada Cephalosporin Drugs Market by Route of Administration

7.2.4 Canada Cephalosporin Drugs Market by Type

7.3 Mexico Cephalosporin Drugs Market

7.3.1 Mexico Cephalosporin Drugs Market by Generation

7.3.2 Mexico Cephalosporin Drugs Market by Application

7.3.3 Mexico Cephalosporin Drugs Market by Route of Administration

7.3.4 Mexico Cephalosporin Drugs Market by Type

7.4 Rest of North America Cephalosporin Drugs Market

7.4.1 Rest of North America Cephalosporin Drugs Market by Generation

7.4.2 Rest of North America Cephalosporin Drugs Market by Application

7.4.3 Rest of North America Cephalosporin Drugs Market by Route of Administration

7.4.4 Rest of North America Cephalosporin Drugs Market by Type

CHAPTER 8. COMPANY PROFILES

8.1 ABBOTT Laboratories

8.1.1 Company Overview

8.1.2 Financial Analysis

8.1.3 Segmental and Regional Analysis

8.1.4 Research & Development Expense

8.1.1 Recent strategies and developments:

8.1.1.1 Collaborations, partnerships and agreements:

8.1.1.2 Acquisition and Mergers:

8.2 Teva Pharmaceutical Industries Ltd.

8.2.1 Company Overview

8.2.2 Financial Analysis

8.2.3 Regional Analysis

8.2.4 Research & Development Expenses

8.2.5 Recent strategies and developments:

8.2.5.1 Product launches:

8.3 Johnson and Johnson

8.3.1 Company Overview

8.3.2 Financial Analysis

8.3.3 Segmental & Regional Analysis

8.3.4 Research & Development Expenses

8.3.5 Recent strategies and developments:

8.3.5.1 Acquisition and Mergers:

8.4 GlaxoSmithKline PLC (GSK)

8.4.1 Company Overview

8.4.2 Financial Analysis

8.4.3 Segmental and Regional Analysis

8.4.4 Research & Development Expense

8.4.5 Recent strategies and developments:

8.4.5.1 Collaborations, partnerships and agreements:

8.4.5.2 Expansion:

8.4.5.3 Approval:

8.5 Pfizer, Inc.

8.5.1 Company Overview

8.5.2 Financial Analysis

8.5.3 Segmental and Regional Analysis

8.5.4 Research & Development Expense

8.5.5 Recent strategies and developments:

8.5.5.1 Collaborations, partnerships and agreements:

8.5.5.2 Product launches:

8.5.5.3 Acquisition and Mergers:

8.6 Merck & Co., Inc.

8.6.1 Company Overview

8.6.2 Financial Analysis

8.6.3 Segmental and Regional Analysis

8.6.4 Research & Development Expenses

8.6.5 Recent strategies and developments:

8.6.5.1 Collaborations, partnerships and agreements:

8.6.5.2 Product launches:

8.7 Bayer AG (Bayer Schering Pharma AG)

8.7.1 Company Overview

8.7.2 Financial Analysis

8.7.3 Segmental and Regional Analysis

8.7.4 Research & Development Expense

8.7.5 Recent strategies and developments:

8.7.5.1 Collaborations, partnerships and agreements:

8.7.5.2 Product launches:

8.8 Baxter International, Inc.

8.8.1 Company Overview

8.8.2 Financial Analysis

8.8.3 Regional Analysis

8.8.4 Research & Development Expense

8.8.5 Recent strategies and developments:

8.8.5.1 Product launches:

8.9 Bristol-Myers Squibb Company

8.9.1 Company overview

8.9.2 Financial Analysis

8.9.3 Regional Analysis

8.9.4 Research & Development Expense

8.9.5 Recent strategies and developments:

8.9.5.1 Collaborations, partnerships and agreements:

8.1 Novartis AG

8.10.1 Company Overview

8.10.2 Financial Analysis

8.10.3 Segmental and Regional Analysis

8.10.4 Research & Development Expense

8.10.5 Recent strategies and developments:

8.10.5.1 Product launches:

8.10.5.2 Acquisition and Mergers:

List Of Tables

LIST OF TABLES

TABLE 1 NORTH AMERICA CEPHALOSPORIN DRUGS MARKET, 2015 - 2018, USD MILLION

TABLE 2 NORTH AMERICA CEPHALOSPORIN DRUGS MARKET, 2019 - 2025, USD MILLION

TABLE 3 NORTH AMERICA CEPHALOSPORIN DRUGS MARKET BY GENERATION, 2015 - 2018, USD MILLION

TABLE 4 NORTH AMERICA CEPHALOSPORIN DRUGS MARKET BY GENERATION, 2019 - 2025, USD MILLION

TABLE 5 NORTH AMERICA FIRST-GENERATION CEPHALOSPORIN DRUGS MARKET BY COUNTRY, 2015 - 2018, USD MILLION

TABLE 6 NORTH AMERICA FIRST-GENERATION CEPHALOSPORIN DRUGS MARKET BY COUNTRY, 2019 - 2025, USD MILLION

TABLE 7 NORTH AMERICA SECOND-GENERATION CEPHALOSPORIN DRUGS MARKET BY COUNTRY, 2015 - 2018, USD MILLION

TABLE 8 NORTH AMERICA SECOND-GENERATION CEPHALOSPORIN DRUGS MARKET BY COUNTRY, 2019 - 2025, USD MILLION

TABLE 9 NORTH AMERICA THIRD-GENERATION CEPHALOSPORIN DRUGS MARKET BY COUNTRY, 2015 - 2018, USD MILLION

TABLE 10 NORTH AMERICA THIRD-GENERATION CEPHALOSPORIN DRUGS MARKET BY COUNTRY, 2019 - 2025, USD MILLION

TABLE 11 NORTH AMERICA FOURTH-GENERATION CEPHALOSPORIN DRUGS MARKET BY COUNTRY, 2015 - 2018, USD MILLION

TABLE 12 NORTH AMERICA FOURTH-GENERATION CEPHALOSPORIN DRUGS MARKET BY COUNTRY, 2019 - 2025, USD MILLION

TABLE 13 NORTH AMERICA FIFTH-GENERATION CEPHALOSPORIN DRUGS MARKET BY COUNTRY, 2015 - 2018, USD MILLION

TABLE 14 NORTH AMERICA FIFTH-GENERATION CEPHALOSPORIN DRUGS MARKET BY COUNTRY, 2019 - 2025, USD MILLION

TABLE 15 NORTH AMERICA CEPHALOSPORIN DRUGS MARKET BY APPLICATION, 2015 - 2018, USD MILLION

TABLE 16 NORTH AMERICA CEPHALOSPORIN DRUGS MARKET BY APPLICATION, 2019 - 2025, USD MILLION

TABLE 17 NORTH AMERICA RESPIRATORY TRACT INFECTION MARKET BY COUNTRY, 2015 - 2018, USD MILLION

TABLE 18 NORTH AMERICA RESPIRATORY TRACT INFECTION MARKET BY

COUNTRY, 2019 - 2025, USD MILLION

TABLE 19 NORTH AMERICA SKIN INFECTION MARKET BY COUNTRY, 2015 - 2018, USD MILLION

TABLE 20 NORTH AMERICA SKIN INFECTION MARKET BY COUNTRY, 2019 - 2025, USD MILLION

TABLE 21 NORTH AMERICA EAR INFECTION MARKET BY COUNTRY, 2015 - 2018, USD MILLION

TABLE 22 NORTH AMERICA EAR INFECTION MARKET BY COUNTRY, 2019 - 2025, USD MILLION

TABLE 23 NORTH AMERICA SEXUALLY TRANSMITTED INFECTION MARKET BY COUNTRY, 2015 - 2018, USD MILLION

TABLE 24 NORTH AMERICA SEXUALLY TRANSMITTED INFECTION MARKET BY COUNTRY, 2019 - 2025, USD MILLION

TABLE 25 NORTH AMERICA OTHERS MARKET BY COUNTRY, 2015 - 2018, USD MILLION

TABLE 26 NORTH AMERICA OTHERS MARKET BY COUNTRY, 2019 - 2025, USD MILLION

TABLE 27 NORTH AMERICA CEPHALOSPORIN DRUGS MARKET BY ROUTE OF ADMINISTRATION, 2015 - 2018, USD MILLION

TABLE 28 NORTH AMERICA CEPHALOSPORIN DRUGS MARKET BY ROUTE OF ADMINISTRATION, 2019 - 2025, USD MILLION

TABLE 29 NORTH AMERICA INJECTIONS MARKET BY COUNTRY, 2015 - 2018, USD MILLION

TABLE 30 NORTH AMERICA INJECTIONS MARKET BY COUNTRY, 2019 - 2025, USD MILLION

TABLE 31 NORTH AMERICA ORAL DRUGS MARKET BY COUNTRY, 2015 - 2018, USD MILLION

TABLE 32 NORTH AMERICA ORAL DRUGS MARKET BY COUNTRY, 2019 - 2025, USD MILLION

TABLE 33 NORTH AMERICA CEPHALOSPORIN DRUGS MARKET BY TYPE, 2015 - 2018, USD MILLION

TABLE 34 NORTH AMERICA CEPHALOSPORIN DRUGS MARKET BY TYPE, 2019 - 2025, USD MILLION

TABLE 35 NORTH AMERICA BRANDED MARKET BY COUNTRY, 2015 - 2018, USD MILLION

TABLE 36 NORTH AMERICA BRANDED MARKET BY COUNTRY, 2019 - 2025, USD MILLION

TABLE 37 NORTH AMERICA GENERIC MARKET BY COUNTRY, 2015 - 2018, USD MILLION

TABLE 38 NORTH AMERICA GENERIC MARKET BY COUNTRY, 2019 - 2025, USD MILLION

TABLE 39 NORTH AMERICA CEPHALOSPORIN DRUGS MARKET BY COUNTRY, 2015 - 2018, USD MILLION

TABLE 40 NORTH AMERICA CEPHALOSPORIN DRUGS MARKET BY COUNTRY, 2019 - 2025, USD MILLION

TABLE 41 USA CEPHALOSPORIN DRUGS MARKET, 2015 - 2018, USD MILLION

TABLE 42 USA CEPHALOSPORIN DRUGS MARKET, 2019 - 2025, USD MILLION

TABLE 43 USA CEPHALOSPORIN DRUGS MARKET BY GENERATION, 2015 - 2018, USD MILLION

TABLE 44 USA CEPHALOSPORIN DRUGS MARKET BY GENERATION, 2019 - 2025, USD MILLION

TABLE 45 USA CEPHALOSPORIN DRUGS MARKET BY APPLICATION, 2015 - 2018, USD MILLION

TABLE 46 USA CEPHALOSPORIN DRUGS MARKET BY APPLICATION, 2019 - 2025, USD MILLION

TABLE 47 USA CEPHALOSPORIN DRUGS MARKET BY ROUTE OF ADMINISTRATION, 2015 - 2018, USD MILLION

TABLE 48 USA CEPHALOSPORIN DRUGS MARKET BY ROUTE OF ADMINISTRATION, 2019 - 2025, USD MILLION

TABLE 49 USA CEPHALOSPORIN DRUGS MARKET BY TYPE, 2015 - 2018, USD MILLION

TABLE 50 USA CEPHALOSPORIN DRUGS MARKET BY TYPE, 2019 - 2025, USD MILLION

TABLE 51 CANADA CEPHALOSPORIN DRUGS MARKET, 2015 - 2018, USD MILLION

TABLE 52 CANADA CEPHALOSPORIN DRUGS MARKET, 2019 - 2025, USD MILLION

TABLE 53 CANADA CEPHALOSPORIN DRUGS MARKET BY GENERATION, 2015 - 2018, USD MILLION

TABLE 54 CANADA CEPHALOSPORIN DRUGS MARKET BY GENERATION, 2019 - 2025, USD MILLION

TABLE 55 CANADA CEPHALOSPORIN DRUGS MARKET BY APPLICATION, 2015 - 2018, USD MILLION

TABLE 56 CANADA CEPHALOSPORIN DRUGS MARKET BY APPLICATION, 2019 - 2025, USD MILLION

TABLE 57 CANADA CEPHALOSPORIN DRUGS MARKET BY ROUTE OF ADMINISTRATION, 2015 - 2018, USD MILLION

TABLE 58 CANADA CEPHALOSPORIN DRUGS MARKET BY ROUTE OF

ADMINISTRATION, 2019 - 2025, USD MILLION

TABLE 59 CANADA CEPHALOSPORIN DRUGS MARKET BY TYPE, 2015 - 2018, USD MILLION

TABLE 60 CANADA CEPHALOSPORIN DRUGS MARKET BY TYPE, 2019 - 2025, USD MILLION

TABLE 61 MEXICO CEPHALOSPORIN DRUGS MARKET, 2015 - 2018, USD MILLION

TABLE 62 MEXICO CEPHALOSPORIN DRUGS MARKET, 2019 - 2025, USD MILLION

TABLE 63 MEXICO CEPHALOSPORIN DRUGS MARKET BY GENERATION, 2015 - 2018, USD MILLION

TABLE 64 MEXICO CEPHALOSPORIN DRUGS MARKET BY GENERATION, 2019 - 2025, USD MILLION

TABLE 65 MEXICO CEPHALOSPORIN DRUGS MARKET BY APPLICATION, 2015 - 2018, USD MILLION

TABLE 66 MEXICO CEPHALOSPORIN DRUGS MARKET BY APPLICATION, 2019 - 2025, USD MILLION

TABLE 67 MEXICO CEPHALOSPORIN DRUGS MARKET BY ROUTE OF ADMINISTRATION, 2015 - 2018, USD MILLION

TABLE 68 MEXICO CEPHALOSPORIN DRUGS MARKET BY ROUTE OF ADMINISTRATION, 2019 - 2025, USD MILLION

TABLE 69 MEXICO CEPHALOSPORIN DRUGS MARKET BY TYPE, 2015 - 2018, USD MILLION

TABLE 70 MEXICO CEPHALOSPORIN DRUGS MARKET BY TYPE, 2019 - 2025, USD MILLION

TABLE 71 REST OF NORTH AMERICA CEPHALOSPORIN DRUGS MARKET, 2015 - 2018, USD MILLION

TABLE 72 REST OF NORTH AMERICA CEPHALOSPORIN DRUGS MARKET, 2019 - 2025, USD MILLION

TABLE 73 REST OF NORTH AMERICA CEPHALOSPORIN DRUGS MARKET BY GENERATION, 2015 - 2018, USD MILLION

TABLE 74 REST OF NORTH AMERICA CEPHALOSPORIN DRUGS MARKET BY GENERATION, 2019 - 2025, USD MILLION

TABLE 75 REST OF NORTH AMERICA CEPHALOSPORIN DRUGS MARKET BY APPLICATION, 2015 - 2018, USD MILLION

TABLE 76 REST OF NORTH AMERICA CEPHALOSPORIN DRUGS MARKET BY APPLICATION, 2019 - 2025, USD MILLION

TABLE 77 REST OF NORTH AMERICA CEPHALOSPORIN DRUGS MARKET BY ROUTE OF ADMINISTRATION, 2015 - 2018, USD MILLION

TABLE 78 REST OF NORTH AMERICA CEPHALOSPORIN DRUGS MARKET BY ROUTE OF ADMINISTRATION, 2019 - 2025, USD MILLION

TABLE 79 REST OF NORTH AMERICA CEPHALOSPORIN DRUGS MARKET BY TYPE, 2015 - 2018, USD MILLION

TABLE 80 REST OF NORTH AMERICA CEPHALOSPORIN DRUGS MARKET BY TYPE, 2019 - 2025, USD MILLION

TABLE 81 KEY INFORMATION – ABBOTT LABORATORIES

TABLE 82 KEY INFORMATION – TEVA PHARMACEUTICALS INDUSTRIES LTD.

TABLE 83 KEY INFORMATION – JOHNSON AND JOHNSON

TABLE 84 KEY INFORMATION – GLAXOSMITHKLINE PLC (GSK)

TABLE 85 KEY INFORMATION – PFIZER, INC.

TABLE 86 KEY INFORMATION – MERCK & CO., INC.

TABLE 87 KEY INFORMATION – BAYER AG

TABLE 88 KEY INFORMATION – BAXTER INTERNATIONAL, INC.

TABLE 89 KEY INFORMATION – BRISTOL-MYERS SQUIBB COMPANY

TABLE 90 KEY INFORMATION – NOVARTIS AG

List Of Figures

LIST OF FIGURES

FIG 1 METHODOLOGY FOR THE RESEARCH

I would like to order

Product name: North America Cephalosporin Drugs Market (2019-2025)

Product link: <https://marketpublishers.com/r/NFFE64039D0EN.html>

Price: US\$ 1,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/NFFE64039D0EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970